Supernus Pharmaceuticals
SUPN
83 hedge funds and large institutions have $298M invested in Supernus Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 20 reducing their positions, and 5 closing their positions.
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
45% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $7.46M
30% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 20
30% more funds holding
Funds holding: 64 → 83 (+19)
28% more capital invested
Capital invested by funds: $234M → $298M (+$64.9M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MRM
Michael R. Murphy
|
+$12.4M |
| 2 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$9.85M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$2.82M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.26M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
-$8.69M |
| 2 |
OHCM
Orchard Hill Capital Management
New York
|
-$8.59M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.35M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.62M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.13M |
SUPN Hedge Fund Activity: Q1 2014 in Review
83 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2014, worth a combined $298M — up 28% from $234M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SUPN positions and 5 closed out — a net gain of 19 holders — while 26 added to existing stakes and 20 trimmed.
The largest buyer was Michael R. Murphy, opening a new position worth an estimated $12.4M. The largest seller was Healthcare Value Capital, cutting an estimated $8.69M.
- 83 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2014, up from 64 in Q4 2013.
- Funds reported $298M of Supernus Pharmaceuticals stock for Q1 2014, up 28% quarter-over-quarter.
- 24 funds opened new Supernus Pharmaceuticals positions in Q1 2014 and 5 closed out, a net change of +19 holders.
- The largest Supernus Pharmaceuticals buyer in Q1 2014 was Michael R. Murphy, an estimated $12.4M added.
- The largest Supernus Pharmaceuticals seller in Q1 2014 was Healthcare Value Capital, an estimated $8.69M sold.
Based on aggregated 13F filings for Q1 2014.